Experimental myeloma drug tasquinimod tested in early trial – but study halted
NCT ID NCT04405167
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called tasquinimod, alone or with standard chemotherapy, in 30 adults with multiple myeloma that had relapsed or become resistant. The main goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tasquinimod (oral capsules), sometimes combined with ixazomib, lenalidomide, and dexamethasone
What this could lead to
If successful, this could point toward a new treatment option for people with multiple myeloma that has come back or not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, now terminated. It was designed mainly to find a safe dose, not to prove effectiveness. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States